NOX1 and Hepatic fibrosis: The use of selective inhibitors to target specific NOX isoforms (such as NOX1 and/or NOX4) is a promising approach to treating liver fibrosis, due to the prevention of HSC activation and protection against hepatocyte injury, although further work is needed to fully confirm the clinical safety of these compounds.